comparemela.com

Latest Breaking News On - Silverarc capital management - Page 7 : comparemela.com

HC Wainwright Analysts Increase Earnings Estimates for Annexon, Inc. (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX – Free Report) – Research analysts at HC Wainwright lifted their Q2 2024 earnings estimates for Annexon in a report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.22) for the quarter, up from their prior forecast of ($0.37). […]

United-states
America
Kennedy-capital-management
Sg-americas-securities
Annexon-inc
Annexon-company-profile
Wells-fargo-company
Sectoral-asset-management-inc
Jpmorgan-chase-co
Cantor-fitzgerald
Silverarc-capital-management

Annexon (NASDAQ:ANNX) Given "Buy" Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Annexon (NASDAQ:ANNX – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Annexon’s Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings […]

United-states
America
Sectoral-asset-management-inc
Sg-americas-securities
Wells-fargo-company
Kennedy-capital-management
Annexon-inc
Forefront-analytics
Jpmorgan-chase-co
Cantor-fitzgerald
Needham-company

Wedbush Reiterates "Outperform" Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush reaffirmed their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $41.00 price target on the stock. Wedbush also issued estimates for Aerovate Therapeutics’ Q2 2024 earnings at ($0.71) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings […]

Alps
Switzerland-general
Switzerland
United-states
Swiss
Marinus-verwijs
Timothyp-noyes
Ikarian-capital
Alps-advisors-inc
Jefferies-financial-group
Aerovate-therapeutics-inc
Wells-fargo-company

Soleno Therapeutics (NASDAQ:SLNO) Given New $59.00 Price Target at Oppenheimer

Soleno Therapeutics (NASDAQ:SLNO – Free Report) had its price target cut by Oppenheimer from $65.00 to $59.00 in a research report report published on Monday, Benzinga reports. They currently have an outperform rating on the stock. A number of other research analysts also recently weighed in on SLNO. Stifel Nicolaus assumed coverage on shares of […]

Bhatnagar-anish
Piper-sandler
Robertw-baird
Stifel-nicolaus
York-mellon-corp
Vivo-opportunity-llc
Soleno-therapeutics-company-profile
Silverarc-capital-management
Soleno-therapeutics-inc
Securities-exchange-commission
Carlyle-group-inc
Vivo-capital

Aerovate Therapeutics (NASDAQ:AVTE) Sees Large Volume Increase

Aerovate Therapeutics (NASDAQ:AVTE) Sees Large Volume Increase
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United-states
Alps
Switzerland-general
Switzerland
Swiss
Benjamint-dake
Aerovate-therapeutics-inc
Eventide-asset-management
Wells-fargo-company
Swiss-national-bank
Aerovate-therapeutics-company-profile
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.